Triple-negative breast cancer (TNBC) is a heterogeneous disease that has high diversity with regard to biology and treatment and an aggressive clinical behavior because of poor differentiation and lack of targeted therapeutics. Based on this heterogeneity and the lack of well-defined molecular targets, the treatment of TNBC patients is highly challenging. Therefore, it is essential to identify additional reliable molecular prognostic markers to allow a better treatment.Aim
The aim of this study was to evaluate the potential prognostic role of L1CAM, androgen receptor (AR), and epithelial growth factor receptor (EGFR) expressions in TNCB and to investigate the association between these markers and the different clinical and pathological data.Materials and methods
The associations between the expression of L1CAM, AR, and EGFR and the clinicopathological variables were evaluated in 55 patients with TNBC using immunohistochemical staining methods.Results
A total of 19 (34.5%) cases were positive for L1CAM, 18 (32%) were positive for AR, whereas 31 (56%) exhibited positivity for EGFR. L1CAM staining was significantly associated with high tumor grade (P=0.001) and lymph-node metastasis (P=0.001). Positive AR staining was inversely associated with lymphovascular invasion (P=0.004) and EGFR expressions (P=0.003). EGFR expression was significantly associated with the presence of necrosis (P=0.001) and tumor grade (P=0.001).Conclusion
Data obtained from this study advocate that L1CAM, AR, and EGFR could be used as useful prognostic markers and potential therapeutic targets for patients with TNBC.